JPMorgan Chase Financial Co. LLC has announced the launch of $240,000 in auto callable contingent interest notes linked to the common stock of Morgan Stanley. This pricing supplement, filed on October 29, 2026, signifies JPMorgan's ongoing efforts to innovate within the structured investment space, catering to investors seeking unique financial products.

The notes are designed for investors who are looking for contingent interest payments based on the stock performance of Morgan Stanley. They will pay interest if the stock price meets certain conditions related to its initial value. This offering is fully and unconditionally guaranteed by JPMorgan Chase & Co., which adds a layer of security for potential investors.

Background

JPMorgan Chase Financial Co. LLC, categorized under the SIC code 6021 for National Commercial Banks, is a subsidiary of JPMorgan Chase & Co. The company is incorporated in Delaware and operates out of New York City. The recent filing is part of a series of filings made on the same day, indicating a proactive approach to capitalizing on market opportunities.

What the Filing Says

The filing details the structure of the notes, stating, "The notes are designed for investors who seek a Contingent Interest Payment with respect to each Review Date for which the closing price of one share of the Reference Stock is greater than or equal to 70.00% of the Initial Value." This highlights the conditional nature of the interest payments and the risks associated with the investment.

Impact

This offering may appeal to a range of investors, particularly those looking for higher yield opportunities linked to stock performance. The notes are also subject to the credit risk of both JPMorgan Financial and its parent company, JPMorgan Chase & Co., making it crucial for investors to assess their risk tolerance.

What's Next

The notes priced on October 27, 2026, and are expected to settle on or about October 30, 2026. Investors interested in participating will need to consider the terms outlined in the pricing supplement and associated risk factors.